![Alkahest.png](https://static.biospace.com/dims4/default/a2b5f54/2147483647/strip/true/crop/360x180+0+0/resize/200x100!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2F45%2Fa5%2F416796d54c9dbea0a4272397bd4c%2Falkahest.png)
Alkahest, Inc.
NEWS
Several biotech companies backed by billions are working on different approaches to developing the next big anti-aging therapy - from blood experiments to cell reprogramming.
Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
The transaction, which is set to conclude in early 2021, will give Grifols access to Alkahest’s four product candidates.
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
It was a very busy week for clinical trial news. Here’s a look.
Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
JOBS
IN THE PRESS